Validation of genomic biomarker in pooled case-cohort studies

Prostate cancer is the most common cancer in men. Radical prostatectomy (RP) is a common treatment for this cancer, and after surgery, patients are still considered at risk. It’s important to accurately identify high risk patients after RP in order to reduce risk through further treatments. The genomic classifier (GC) DecipherTM, a product of GenomeDx […]

Read More